Form 4: Cue Biopharma Executive Receives Equity Grant

Ray Sumita, Chief Legal Compliance Officer and Corporate Secretary at Cue Biopharma, Inc., was granted restricted and performance stock units.

Summary

• Ray Sumita, Chief Legal Compliance Officer and Corporate Secretary of Cue Biopharma, Inc., received a grant of equity awards on July 9, 2026.
• The grant includes 54,589 restricted stock units (RSUs) and 54,589 performance stock units (PSUs).
• The RSUs vest in equal quarterly installments over 48 months, contingent on continued service.
• The PSUs have stock-price based vesting conditions tied to achieving closing prices of $33.00, $38.50, and $44.00 for five consecutive trading days.
• If PSU stock price targets are not met within 24 months of the grant date, the PSUs will be forfeited.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on routine executive equity grants rather than significant financial or strategic developments.

Positives

• Grant of equity awards to a key executive, indicating continued investment in leadership and potential future value.
• Performance-based component of PSUs aligns executive compensation with stock price appreciation, benefiting shareholders.
• RSUs provide a steady incentive over a 48-month period, promoting long-term commitment.

Negatives

• The vesting of PSUs is contingent on achieving specific stock price targets, which may not be met.
• PSUs will be forfeited if stock price targets are not met within 24 months, representing a potential loss of incentive.

Risks

• Failure to achieve the specified stock price targets ($33.00, $38.50, $44.00) for the PSUs within the 24-month period.
• The reporting person's continued service with the issuer is a condition for RSU vesting, implying a risk of forfeiture if employment ceases.

Future Outlook

The future outlook for the PSUs is dependent on the company's stock performance reaching specific price thresholds within defined timeframes. The RSUs provide a more predictable future incentive tied to continued employment.

Industry Context

StockSavvy.ai notes that equity grants, particularly those with performance-based vesting conditions like PSUs, are a common practice in the biopharmaceutical industry to attract and retain executive talent and align their interests with shareholder value creation. The specific stock price targets set by Cue Biopharma reflect a growth-oriented strategy.

Stakeholder Impact

• Shareholders: The performance-based nature of PSUs aligns executive incentives with potential stock price appreciation, which can benefit shareholders if targets are met.
• Employees: The grant to a senior executive may signal confidence in the company's future, potentially boosting morale.
• Management: The grant provides significant incentive for continued service and performance.

Next Steps

• Vesting of RSUs in quarterly installments over 48 months.
• Achievement of stock price targets for PSU vesting within 24 months from the grant date.
• Potential forfeiture of PSUs if stock price targets are not met by the specified deadline.

Key Dates

Keywords

Cue Biopharma, CUE, Form 4, Equity Grant, Restricted Stock Units, Performance Stock Units, Executive Compensation, Stock Options, SEC Filing, Insider Trading